Introduction and Objective: Pancreas size declines in individuals progressing from Stage 1/2 to Stage 3 T1D. Whether teplizumab treatment, which delays progression to Stage 3 T1D, affects pancreas size is not known. Methods: We performed longitudinal MRI using a standardized protocol at two sites (27 MRIs total) in ten individuals with Stage 2 T1D (mean age 16, range 9 - 64, 30% female) treated with teplizumab. Pancreas volume was quantified by a blinded reader and divided by body weight to yield pancreas volume index (PVI). Results: Individuals treated with teplizumab displayed a wide range of baseline PVI at infusion (0.37 ml/kg to 1.68 ml/kg). The mean baseline PVI was 0.85 ml/kg, similar to established PVI in Stage 1 and 2 T1D (PMID: 38151474). PVI transiently increased in individuals treated with teplizumab at ~six months post-infusion. In contrast, PVI was stable in individuals with Stage 1 or Stage 2 T1D not treated with Teplizumab (PMID: 38151474) who do not progress to Stage 3. Conclusion: These data suggest that teplizumab induces a transient increase in pancreas size six months post infusion which returns to baseline one year post infusion. Ongoing studies will determine how initial volume and dynamic changes correspond to treatment outcomes. Disclosure J. Virostko: None. J. Wright: None. J. Williams: None. D. Braun: None. M.A. Hilmes: None. S.W. Greeley: None. A.C. Powers: None. D.J. Moore: Advisory Panel; Current; Sanofi-Aventis U.S. Funding Helmsley Charitable Trust (2201-05374)
Virostko et al. (Fri,) studied this question.